Toll Free : + 1-888-961-4454 | Int'l : + 91 (788) 802-9103 | support@researchdive.com
LI23018596 |
Pages: 240 |
Jan 2023 |
An infection of the urinary system, including the lower urinary tract or both the lower and upper urinary tracts, is known as a urinary tract infection (UTI). It occurs because microbes such as bacteria overcome the body’s defenses in the urinary tract and impact the bladder, kidneys, and the tubes that run between them. Women, immunocompromised people, older people, and patients using catheters and undergoing radiotherapy treatment are more prone to complicated UTIs. In addition, people with blockages and kidney function problems have higher chances of developing a critical UTI. Compared to men, women are more prone to UTIs. When it comes to adult women, disease incidence tends to rise with age.
The increase in geriatric population worldwide is anticipated to propel the urinary tract infection testing market growth during the forecast period. According to the World Health Organization (WHO), by the year 2030, 1 in 6 people across the world will be aged 60 years or over. UTIs occur more frequently in aging people, especially, in those who are in long-term care facilities. As the aging population increases worldwide, the burden of UTIs is anticipated to increase, thus, increasing the need for urinary tract infection testing.
False results from UTI testing, however, can hamper the urinary tract infection testing market demand. Rapid testing or dipstick tests can produce false-positive findings in one out of every five patients. The availability of at-home sample collection kits and self-testing kits for UTI testing is likely to offer ample growth opportunities to major market players. A home test kit, for instance, is offered in the UK by Healthy.io Ltd. Major players are anticipated to boost their investments in point-of-care testing for UTIs, which will be an important growth factor. Furthermore, researchers are developing cutting-edge medical diagnostic tools that will likely be commercialized in the coming years.
A urinary tract infection (UTI) is an infection in the urinary system, including the bladder and urethra. If UTI is not diagnosed on time, it can cause kidney disease. UTI is caused by the bacteria that live in the genital, vagina, and anal areas. These bacteria can enter the urethra and the bladder and induce an infection. UTI can also be caused by gonorrhea, chlamydia, or other organisms.
The major symptoms in patients with COVID-19 are generally associated with the respiratory organ system. Some studies have also discovered the involvement of other organ systems, including the cardiovascular, gastrointestinal, central nervous, and lower urinary tract systems. The lower urinary tract symptoms can be severe, depending on the severity of the infection from COVID-19. Various studies have shown white blood cells and hematuria in the urine of a patient with COVID-19. UTIs caused by COVID-19 infection are more common in men than women and patients who are admitted to the hospital because of severe coronavirus infection. Pain in the male genitals is the most common symptom of UTIs caused by COVID-19.
UTIs are one of the most frequently diagnosed infections impacting the human population across the world, with a lifetime occurrence of 50−60% in adult women. Several evaluations show that around 150 million people are diagnosed with UTI every year, which causes severe complications if left untreated. Except for a spike in young women aged between 14−24 years, the occurrence of UTIs grows with age. Moreover, the prevalence in women aged over 65 years of age is about 20%, compared with approximately 11% in the overall population.
UTIs can impact the quality of life of the patient and puts a clinical and financial burden on the patient. Due to this and other mentioned factors, the need for urinary tract infection testing is rising.
To know more about the global urinary tract infection testing market drivers, get in touch with our analysts here.
According to several studies, urinary tract infections wrongly show a negative result in a fifth of cases. Many times, patients can receive negative results for a urine test, but can still exhibit symptoms of UTIs. Exposing patients to poor test results lead to false positive or false negative results. Doctors usually act on these false results, which can cause undue evaluation and treatment. Such testing errors increase uncertainty and confusion among the patients.
Companies are anticipated to increase their investments in point-of-care (POC) testing for UTIs, which is likely to offer ample growth opportunities. POC testing for UTIs can reduce the time required to get a precise diagnosis, offers doctors specific guidance on which antibiotics to prescribe for maximum therapeutic use, and ease the laboratory load of urine specimens and associated costs. Researchers are developing cutting-edge medical diagnostic tools that will likely be commercialized in the coming years. These are some of the major factors which are anticipated to provide major participants in the market with lucrative growth prospects during the forecast period.
To know more about the global urinary tract infection testing market opportunities, get in touch with our analysts here.
On the basis of infection type, the market is divided into urethritis, cystitis, and pyelonephritis. Among these, the cystitis segment accounted for the highest market share in 2021 and is expected to remain dominant during the forecast period.
Source: Research Dive Analysis
The cystitis segment had a dominant market share in 2021. Cystitis can be either complicated or uncomplicated. Acute cystitis is most commonly caused by a bacterial infection of the urinary bladder. Generally, women are more affected because the rectum is closer to the urethral meatus and due to the short urethral length in females. Most women will encounter cystitis at least once in their lifetimes. If cystitis is not treated on time, the infection can go back into the urinary system from the bladder and reach the kidneys. A kidney infection is critical and requires rapid medical attention as it can cause kidney failure.
The pyelonephritis segment is anticipated to grow at the fastest CAGR during the forecast period. Pyelonephritis is a urinary tract infection that advances to the upper urinary tract from the lower urinary tract. Acute pyelonephritis is a bacterial infection related to the kidney. Pyelonephritis can be fatal and frequently leads to scarring of the kidney. Tests that require the insertion of an instrument into the bladder also augment pyelonephritis chances. The two major signs of pyelonephritis are discomfort in the area just under the lower ribs in the back along with fever. Uncomplicated pyelonephritis symptoms start to improve after two to three days of treatment.
On the basis of test type, the market is classified into urinalysis, urine culture, and susceptibility testing. Among these, the urinalysis segment accounted for the highest revenue share in 2021.
Source: Research Dive Analysis
The urinalysis segment is anticipated to have a dominant market share during the forecast period. With the increasing geriatric population across the globe, the need for urinalysis is anticipated to boost during the forecast period. Aging people are more prone to urinary tract infections. Urinalysis is the most useful test for the diagnosis of UTIs. The precise interpretation of urinalysis is important for doctors to analyze and treat urinary tract-infected patients properly. There are numerous aspects to consider when assessing urinalysis for indicators of infection. The most common indicator is the presence of bacteria in the urine.
On the basis of end user, the market is divided into hospitals, diagnostic laboratories, and research institutes. Among these, the diagnostic laboratories segment is anticipated to grow at the fastest CAGR during the forecast period.
Source: Research Dive Analysis
The diagnostic laboratories segment is anticipated to have a dominant market share and the fastest CAGR during the forecast period. The number of UTI tests performed in diagnostic laboratories is anticipated to increase in the coming years. Diagnostic laboratories can be either public or private and are generally equipped with appropriate and costly instrumentation. However, there is a need for highly trained staff and qualified people to conduct the tests. Technological advances in data management are anticipated to further supplement the segment growth.
On the basis of test kit, the market is classified into home test kit and laboratory test kit. Among these, the laboratory test kit segment accounted for the highest market share in 2021.
Source: Research Dive Analysis
The laboratory test kits segment is anticipated to have a dominant market share. The urinary tract infection laboratory test kit helps to keep track of nitrites, leukocytes, blood, pH, and other parameters in urine to diagnose UTIs. This test kit provides precise results on a smartphone within 30 seconds. Patients can re-check if they are infection-free or not easily using these UTI test kits.
The urinary tract infection testing market was investigated across North America, Europe, Asia-Pacific, and LAMEA.
Source: Research Dive Analysis
UTIs are the most common infections in females in the United States (U.S.), accounting for around 6 million patient visits to doctors every year. The economic impact of UTIs is a significant factor impacting healthcare expenditures. Both inpatient and outpatient treatment contribute to overall expenses. Urinary tract infection most often occurs in hospitals owing to indwelling catheters. In Canada, around 50 percent of aging people who are in long-term care establishments have bacteria in their urine without symptoms of a urinary tract infection. Due to these factors, the demand for urinary tract infection testing is anticipated to propel in North America.
Investments, product launches, and agreements are common strategies followed by the major market players. For instance, in 2019, Scanwell Health launched a smartphone-powered home test for urinary tract infection testing.
Source: Research Dive Analysis
Some of the leading urinary tract infection testing market players are F. Hoffmann-La Roche Ltd, Stryker, Abbott, Siemens, Sysmex Corporation, Cardinal Health, Danaher, Quidel, Bio-Rad Laboratories, Inc., and ACON Labs.
Aspect | Particulars |
Historical Market Estimations | 2020 |
Base Year for Market Estimation | 2021 |
Forecast Timeline for Market Projection | 2022-2031 |
Geographical Scope | North America, Europe, Asia-Pacific, and LAMEA |
Segmentation by Infection type |
|
Segmentation by Test type |
|
Segmentation by End User |
|
Segmentation by Test kit |
|
Key Companies Profiled |
|
1.Research Methodology
1.1.Desk Research
1.2.Real time insights and validation
1.3.Forecast model
1.4.Assumptions and forecast parameters
1.5.Market size estimation
1.5.1.Top-down approach
1.5.2.Bottom-up approach
2.Report Scope
2.1.Market definition
2.2.Key objectives of the study
2.3.Report overview
2.4.Market segmentation
2.5.Overview of the impact of COVID-19 on Global urinary tract infection testing market
3.Executive Summary
4.Market Overview
4.1.Introduction
4.2.Growth impact forces
4.2.1.Drivers
4.2.2.Restraints
4.2.3.Opportunities
4.3.Market value chain analysis
4.3.1.List of component providers
4.3.2.List of manufacturers
4.3.3.List of distributors
4.4.Innovation & sustainability matrices
4.4.1.Technology matrix
4.4.2.Regulatory matrix
4.5.Porter’s five forces analysis
4.5.1.Bargaining power of suppliers
4.5.2.Bargaining power of consumers
4.5.3.Threat of substitutes
4.5.4.Threat of new entrants
4.5.5.Competitive rivalry intensity
4.6.PESTLE analysis
4.6.1.Political
4.6.2.Economical
4.6.3.Social
4.6.4.Technological
4.6.5.Environmental
4.7.Impact of COVID-19 on Urinary Tract Infection Testing market
4.7.1.Pre-covid market scenario
4.7.2.Post-covid market scenario
5. Urinary Tract Infection Testing Market Analysis, by Infection Type
5.1.Overview
5.2.Urethritis
5.2.1.Definition, key trends, growth factors, and opportunities
5.2.2.Market size analysis, by region
5.2.3.Market share analysis, by country
5.3.Cystitis
5.3.1.Definition, key trends, growth factors, and opportunities
5.3.2.Market size analysis, by region
5.3.3.Market share analysis, by country
5.4.Pyelonephritis
5.4.1.Definition, key trends, growth factors, and opportunities
5.4.2.Market size analysis, by region
5.4.3.Market share analysis, by country
5.5.Research Dive Exclusive Insights
5.5.1.Market attractiveness
5.5.2.Competition heatmap
6.Urinary Tract Infection Testing Market Analysis, by Test Type
6.1.Urinalysis
6.1.1.Definition, key trends, growth factors, and opportunities
6.1.2.Market size analysis, by region
6.1.3.Market share analysis, by country
6.2.Urine Cultures
6.2.1.Definition, key trends, growth factors, and opportunities
6.2.2.Market size analysis, by region
6.2.3.Market share analysis, by country
6.3.Susceptibility Testing
6.3.1.Definition, key trends, growth factors, and opportunities
6.3.2.Market size analysis, by region
6.3.3.Market share analysis, by country
6.4.Research Dive Exclusive Insights
6.4.1.Market attractiveness
6.4.2.Competition heatmap
7.Urinary Tract Infection Testing Market Analysis, by End User
7.1.Hospitals
7.1.1.Definition, key trends, growth factors, and opportunities
7.1.2.Market size analysis, by region
7.1.3.Market share analysis, by country
7.2.Diagnostic Laboratories
7.2.1.Definition, key trends, growth factors, and opportunities
7.2.2.Market size analysis, by region
7.2.3.Market share analysis, by country
7.3.Research Institutes
7.3.1.Definition, key trends, growth factors, and opportunities
7.3.2.Market size analysis, by region
7.3.3.Market share analysis, by country
7.4.Research Dive Exclusive Insights
7.4.1.Market attractiveness
7.4.2.Competition heatmap
8.Urinary Tract Infection Testing Market Analysis, by Test Kit
8.1. Home Test Kits
8.1.1.Definition, key trends, growth factors, and opportunities
8.1.2.Market size analysis, by region
8.1.3.Market share analysis, by country
8.2.Laboratory Test Kits
8.2.1.Definition, key trends, growth factors, and opportunities
8.2.2.Market size analysis, by region
8.2.3.Market share analysis, by country
8.3.Research Dive Exclusive Insights
8.3.1.Market attractiveness
8.3.2.Competition heatmap
9.Urinary Tract Infection Testing Market, by Region
9.1.North America
9.1.1.U.S.
9.1.1.1.Market size analysis, by Infection Type
9.1.1.2.Market size analysis, by Test Type
9.1.1.3.Market size analysis, by End User
9.1.1.4.Market size analysis, by Test Kit
9.1.2.Canada
9.1.2.1.Market size analysis, by Infection Type
9.1.2.2.Market size analysis, by Test Type
9.1.2.3.Market size analysis, by End User
9.1.2.4.Market size analysis, by Test Kit
9.1.3.Mexico
9.1.3.1.Market size analysis, by Infection Type
9.1.3.2.Market size analysis, by Test Type
9.1.3.3.Market size analysis, by End User
9.1.3.4.Market size analysis, by Test Kit
9.1.4.Research Dive Exclusive Insights
9.1.4.1.Market attractiveness
9.1.4.2.Competition heatmap
9.2.Europe
9.2.1.Germany
9.2.1.1.Market size analysis, by Infection Type
9.2.1.2.Market size analysis, by Test Type
9.2.1.3.Market size analysis, by End User
9.2.1.4.Market size analysis, by Test Kit
9.2.2.UK
9.2.2.1.Market size analysis, by Infection Type
9.2.2.2.Market size analysis, by Test Type
9.2.2.3.Market size analysis, by End User
9.2.2.4.Market size analysis, by Test Kit
9.2.3.France
9.2.3.1.Market size analysis, by Infection Type
9.2.3.2.Market size analysis, by Test Type
9.2.3.3.Market size analysis, by End User
9.2.3.4.Market size analysis, by Test Kit
9.2.4.Spain
9.2.4.1.Market size analysis, by Infection Type
9.2.4.2.Market size analysis, by Test Type
9.2.4.3.Market size analysis, by End User
9.2.4.4.Market size analysis, by Test Kit
9.2.5.Italy
9.2.5.1.Market size analysis, by Infection Type
9.2.5.2.Market size analysis, by Test Type
9.2.5.3.Market size analysis, by End User
9.2.5.4.Market size analysis, by Test Kit
9.2.6.Rest of Europe
9.2.6.1.Market size analysis, by Infection Type
9.2.6.2.Market size analysis, by Test Type
9.2.6.3.Market size analysis, by End User
9.2.6.4.Market size analysis, by Test Kit
9.2.7.Research Dive Exclusive Insights
9.2.7.1.Market attractiveness
9.2.7.2.Competition heatmap
9.3.Asia-Pacific
9.3.1.China
9.3.1.1.Market size analysis, by Infection Type
9.3.1.2.Market size analysis, by Test Type
9.3.1.3.Market size analysis, by End User
9.3.1.4.Market size analysis, by Test Kit
9.3.2.Japan
9.3.2.1.Market size analysis, by Infection Type
9.3.2.2.Market size analysis, by Test Type
9.3.2.3.Market size analysis, by End User
9.3.2.4.Market size analysis, by Test Kit
9.3.3.India
9.3.3.1.Market size analysis, by Infection Type
9.3.3.2.Market size analysis, by Test Type
9.3.3.3.Market size analysis, by End User
9.3.3.4.Market size analysis, by Test Kit
9.3.4.Australia
9.3.4.1.Market size analysis, by Infection Type
9.3.4.2.Market size analysis, by Test Type
9.3.4.3.Market size analysis, by End User
9.3.4.4.Market size analysis, by Test Kit
9.3.5.South Korea
9.3.5.1.Market size analysis, by Infection Type
9.3.5.2.Market size analysis, by Test Type
9.3.5.3.Market size analysis, by End User
9.3.5.4.Market size analysis, by Test Kit
9.3.6.Rest of Asia-Pacific
9.3.6.1.Market size analysis, by Infection Type
9.3.6.2.Market size analysis, by Test Type
9.3.6.3.Market size analysis, by End User
9.3.6.4.Market size analysis, by Test Kit
9.3.7.Research Dive Exclusive Insights
9.3.7.1.Market attractiveness
9.3.7.2.Competition heatmap
9.4.LAMEA
9.4.1.Brazil
9.4.1.1.Market size analysis, by Infection Type
9.4.1.2.Market size analysis, by Test Type
9.4.1.3.Market size analysis, by End User
9.4.1.4.Market size analysis, by Test Kit
9.4.2.Saudi Arabia
9.4.2.1.Market size analysis, by Infection Type
9.4.2.2.Market size analysis, by Test Type
9.4.2.3.Market size analysis, by End User
9.4.2.4.Market size analysis, by Test Kit
9.4.3.UAE
9.4.3.1.Market size analysis, by Infection Type
9.4.3.2.Market size analysis, by Test Type
9.4.3.3.Market size analysis, by End User
9.4.3.4.Market size analysis, by Test Kit
9.4.4.South Africa
9.4.4.1.Market size analysis, by Infection Type
9.4.4.2.Market size analysis, by Test Type
9.4.4.3.Market size analysis, by End User
9.4.4.4.Market size analysis, by Test Kit
9.4.5.Rest of LAMEA
9.4.5.1.Market size analysis, by Infection Type
9.4.5.2.Market size analysis, by Test Type
9.4.5.3.Market size analysis, by End User
9.4.5.4.Market size analysis, by Test Kit
9.4.6.Research Dive Exclusive Insights
9.4.6.1.Market attractiveness
9.4.6.2.Competition heatmap
10.Competitive Landscape
10.1.Top winning strategies, 2021
10.1.1.By strategy
10.1.2.By year
10.2.Strategic overview
10.3.Market share analysis, 2021
11.Company Profiles
11.1.F. Hoffmann-La Roche Ltd
11.1.1.Overview
11.1.2.Business segments
11.1.3.Product portfolio
11.1.4.Financial performance
11.1.5.Recent developments
11.1.6.SWOT analysis
11.2.Stryker
11.2.1.Overview
11.2.2.Business segments
11.2.3.Product portfolio
11.2.4.Financial performance
11.2.5.Recent developments
11.2.6.SWOT analysis
11.3.Abbott
11.3.1.Overview
11.3.2.Business segments
11.3.3.Product portfolio
11.3.4.Financial performance
11.3.5.Recent developments
11.3.6.SWOT analysis
11.4.Siemens
11.4.1.Overview
11.4.2.Business segments
11.4.3.Product portfolio
11.4.4.Financial performance
11.4.5.Recent developments
11.4.6.SWOT analysis
11.5.Sysmex Corporation
11.5.1.Overview
11.5.2.Business segments
11.5.3.Product portfolio
11.5.4.Financial performance
11.5.5.Recent developments
11.5.6.SWOT analysis
11.6.Cardinal Health
11.6.1.Overview
11.6.2.Business segments
11.6.3.Product portfolio
11.6.4.Financial performance
11.6.5.Recent developments
11.6.6.SWOT analysis
11.7.Danaher
11.7.1.Overview
11.7.2.Business segments
11.7.3.Product portfolio
11.7.4.Financial performance
11.7.5.Recent developments
11.7.6.SWOT analysis
11.8.Quidel
11.8.1.Overview
11.8.2.Business segments
11.8.3.Product portfolio
11.8.4.Financial performance
11.8.5.Recent developments
11.8.6.SWOT analysis
11.9.Bio-Rad Laboratories, Inc.
11.9.1.Overview
11.9.2.Business segments
11.9.3.Product portfolio
11.9.4.Financial performance
11.9.5.Recent developments
11.9.6.SWOT analysis
11.10.ACON Labs.
11.10.1.Overview
11.10.2.Business segments
11.10.3.Product portfolio
11.10.4.Financial performance
11.10.5.Recent developments
11.10.6.SWOT analysis
* Taxes/Fees, If applicable will be added during checkout. All prices in USD.
Have a question ?
Enquire To BuyNeed to add more ?
Request Customization